Market Currents

• Tuesday, April 28, 2009

• 12:13 PM Bayer (BAYRY.PK) halts the trial of its skin-cancer drug after the treatment proved less effective than hoped, but maintains its sale guidance on the drug, which can be used to treat other cancers as well. 1 Comment

• Wednesday, December 10, 2008

• 09:21 AM New blood-thinning medicines could reap billions of dollars for Johnson & Johnson (JNJ), Bayer (BAYRY.PK) and Boehringer Ingelheim. Until now, docs have used a 60-year old pill sold by Bristol-Myers (BMY). Comment!

• Wednesday, October 29, 2008

• 06:54 AM The FDA warns Bayer (BAYRY.PK) for illegally marketing two unapproved over-the-counter medicines combining aspirin with dietary supplements. Bayer says it stands behind 'both products and all the marketing claims that we make in their support.' Comment!
• 06:37 AM Bayer's (BAYRY.PK) Q3 profit fell after a one-time tax benefit in the previous year. Net income -76% to €277M ($353M) vs. €1.18B the previous year, and short of the €302M consensus. Sales +2% to €7.95B. Bayer still expects 2008 sales of around €33B. Comment!

• Friday, October 3, 2008

• 06:10 AM Arthur Higgins, CEO of Bayer AG's health-care unit (BAYRY.PK), says the company is well-positioned to take advantage of other firms' weaknesses during the financial crisis, and will be on the lookout for acquisitions in the coming months, Comment!

• Tuesday, September 9, 2008

• 06:27 AM Bayer (BAYRY.PK) shares rise on rumors that Pfizer (PFE) may make a bid for the company. Pfizer has a history of doing mega-deals but past acquisitions have disappointed investors who want to see Pfizer rely less on aging blockbusters. Comment!